2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 976

Identification of Novel Genes Associated with Dysregulation of B Cells in Patients with Primary Sjögren’s Syndrome
Abstract Number: 201

Identification of Patients with Rheumatoid Arthritis Treated with Biologics Using Standardized Vocabularies
Abstract Number: 598

Identification of Potential Risk Factors for Spinal Structural Damage in Chinese Patients with Ankylosing Spondylitis
Abstract Number: 2780

Identification of SLE Subgroups at Risk for Poor Outcomes After Hydroxychloroquine Taper or Discontinuation
Abstract Number: 1746

Identifying Additional Risk Factors for Arterial and Venous Thrombosis Among Pediatric Antiphospholipid Antibodies Carriers
Abstract Number: 180

Identifying Comorbidities and Seropositivity in Rheumatoid Arthritis Patients Using Single-specialty Electronic Health Record Data
Abstract Number: 1796

Identifying Educational Themes and Knowledge Gaps Through Analysis of Electronic Consultation (eConsult) Communication Between Primary Care Physicians and Rheumatologists
Abstract Number: 964

Identifying Jo-1-Specific B Cells in the Primary Immune Repertoire in Idiopathic Inflammatory Myopathies
Abstract Number: 1717

Identifying Patterns of Histopathologic Presentation in CNS Vasculitis
Abstract Number: 136

Identifying Phenotypes of Patients with Antiphospholipid Antibodies: Results from a Cluster Analysis in a Large Cohort of Patients
Abstract Number: 2535

Identifying Subgroups of SLE Patients with Differential Responses to a BLyS Inhibitor: Application of a Machine Learning Algorithm to Clinical Trial Data
Abstract Number: 386

Idiopathic Granulomatous Mastitis: The Role of Rheumatologists in Treating This Rare Cause of Breast Pain
Abstract Number: 1284

Idiopathic Inflammatory Myopathies: Are Muscle Biopsies Still Needed?
Abstract Number: 2568

Iguratimod Is an Alternative Option for Refractory Lupus Nephritis: A Preliminary Observational Study
Abstract Number: 2745

Iguratimod Treated Scleroderma with Interrupted Egr1/TGF-β Loop

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].